Since its establishment in 2017, Zencore Biologics has become the industry leader in large-scale mammalian cell culture technology. Our team has recorded the highest expression level ever achieved in the fed-batch culture process for antibody production, which currently stands at 15 g/L.
Working with our industry and academic customers all over the world, Zencore has supported the development and manufacture of protein drugs for unmet medical needs. Hundreds of antibodies, which were produced using Zencore's technology platforms, have progressed through various stages of clinical development. To date, Zencore Biologics has helped customers complete 14 IND and 2 BLA projects. The overall project experiences for Zencore has reached 200 plus, which includes 50+ mAbs , 30+ BsAbs, 20+ ADCs, and 90+ other forms of recombinant proteins.
Zencore's leadership team continues to nurture a culture of caring the best interests of our customers while relentlessly pursuing scientific excellence. Adhering to the spirit of "explore and expand our knowledge, strive for excellence", Zencore values quality, leverages the best science and technology for biologic R&D and manufacturing, and provides superb and cost-efficient one-stop-shop CDMO services for biopharmaceutical industries.
Adhering to our value of " Pursue the Facts, Commit the Utmost, Strive for Excellence ", Zencore values the highest quality, mobilizes the best scientific and technological solutions in pharmaceutical R&D and manufacturing, and aims to provide the best and cost-effective one-stop-shop CDMO services for our customers.
Quality
Efficiency
Value
Consistency
Fast turn around
Low cost
Robustness and scalability
Services
Communication
Zencore has a high-caliber professional management team, an enabling organization, and a highly attractive incentive structure to drive the success of our customers and employees.
Zencore senior management team members have many years of experience in MNCs and led and supported the successful filings of dozens of INDs and BLAs. Our project managers, who all have strong technical background, enable an effective and timely communication with our customers.
Our experienced and dedicated team at Zencore Biologics provided reliable and quality services to the anti-PD-1 antibody project from the early R&D phase and to later production phase. We were deeply involved in many aspects of the anti-PD-1 antibody development, such as process development, media formula development, engineering scale-up, process characterization, and development of the antibody production process for high-yield cell culture. Our complete service offering enabled the successful approval and listing of the anti-PD-1 antibody, Toripalimab, of TopAlliance. As of now, Zencore Biologics and TopAlliance are still cooperating on media formula optimization to lower production costs for Toripalimab for expanding the market share.